Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 3/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.37 |
| ▸ | GUCY1B2 | O75343 | 6/20 | 0.37 |
| ▸ | GUCY1A2 | P33402 | 6/20 | 0.37 |
| ▸ | GUCY1A1 | Q02108 | 6/20 | 0.37 |
| ▸ | GUCY1B1 | Q02153 | 6/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GCK | P35557 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18156224 | 0.95 | PTGER1 (0.40) | PTGER1MRGPRX4GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL18178363 | 0.94 | PTGER1 (0.40) | PTGER1MRGPRX4GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL18178151 | 0.93 | MRGPRX4 (0.37) | PTGER1MRGPRX4GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL18178153 | 0.93 | SLC22A12 (0.39) | PTGER1MRGPRX4GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL18178152 | 0.90 | PTGER1 (0.38) | PTGER1MRGPRX4MAPK14 | |
| SCHEMBL18178170 | 0.90 | MRGPRX4 (0.35) | PTGER1MRGPRX4GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL18178164 | 0.90 | MAPT (0.36) | PTGER1MRGPRX4MAPK14KDM4EHPGD | |
| SCHEMBL18178181 | 0.90 | PTGER1 (0.36) | PTGER1MRGPRX4MAPK14KDM4EHPGD | |
| SCHEMBL18178262 | 0.90 | SGMS2 (0.39) | PTGER1KDM4E | |
| SCHEMBL18178118 | 0.90 | MRGPRX4 (0.42) | PTGER1MRGPRX4GUCY1B2GUCY1A2GUCY1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573904-B2 | Aromatic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | ZCCHC8, CBR3, CBX8 | PTGER1 4234/4885MRGPRX4 167/4885GUCY1B2 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.